Daito PharmaceuticalLtd First Quarter 2025 Earnings: EPS: JP¥40.41 (vs JP¥47.55 in 1Q 2024)

Simply Wall St · 10/16 22:06

Daito PharmaceuticalLtd (TSE:4577) First Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥12.7b (up 4.1% from 1Q 2024).
  • Net income: JP¥618.0m (down 9.5% from 1Q 2024).
  • Profit margin: 4.9% (down from 5.6% in 1Q 2024). The decrease in margin was driven by higher expenses.
  • EPS: JP¥40.41 (down from JP¥47.55 in 1Q 2024).
earnings-and-revenue-growth
TSE:4577 Earnings and Revenue Growth October 16th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Daito PharmaceuticalLtd Earnings Insights

Looking ahead, revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for Daito PharmaceuticalLtd that you need to be mindful of.